TOLLerant · Project

New Drug Compounds Targeting Inflammation, Allergies, Asthma, and Sepsis via Immune Receptor TLR4

healthPrototypeTRL 3Thin data (2/5)

Your immune system has a doorbell called TLR4 — when bacteria ring it, your body launches an inflammatory response. Sometimes this doorbell gets stuck, causing chronic inflammation, allergies, asthma, or even sepsis. The TOLLerant team designed chemical compounds that can either block or activate this doorbell on demand. They tested these compounds in animal models of diseases that still lack proper drugs, aiming to create a new generation of anti-inflammatory treatments and better vaccine boosters.

By the numbers

consortium partners across the project

countries involved (BE, DE, ES, IT, SI)

industry partners in the consortium

project deliverables produced

research organizations in the consortium

The business problem

What needed solving

Millions of patients with autoimmune disorders, chronic allergies, asthma, and sepsis still lack targeted treatments because the TLR4 immune receptor — a key driver of inflammation — has no approved modulators on the market. Pharmaceutical companies need validated lead compounds and screening tools to build drug pipelines against this target, but the chemistry and biology of TLR4 is complex and requires multi-disciplinary expertise that few single organizations possess.

The solution

What was built

The project produced synthetic and natural TLR4 modulator compounds (both agonists and antagonists), validated protocols for molecular modelling of TLR4 interactions, and pre-clinical evidence from animal disease models. In total, 10 deliverables were generated, including the molecular modelling protocols as a demonstrated output.

Audience

Who needs this

Pharma companies with inflammation and autoimmune disease pipelinesVaccine developers seeking next-generation adjuvantsBiotech startups focused on immunology drug discoveryContract research organizations offering immunology screening servicesAcademic spin-offs commercializing innate immunity research

Business applications

Who can put this to work

Pharmaceuticals

enterprise

Target: Drug development companies working on inflammatory and autoimmune diseases

If you are a pharma company struggling to find effective treatments for chronic inflammatory diseases like asthma or allergies — this project developed synthetic and natural TLR4 modulators (both agonists and antagonists) tested in animal models. The consortium of 10 partners across 5 countries produced protocols for molecular modelling that can accelerate your own drug candidate screening. With compounds targeting an immune receptor linked to autoimmune disorders, chronic inflammation, and sepsis, these are potential lead molecules for your pipeline.

Vaccine Development

any

Target: Biotech companies developing next-generation vaccines

If you are a vaccine manufacturer looking for better adjuvants to boost immune response — this project investigated TLR4 agonists specifically designed as vaccine adjuvants. The team combined chemistry, biology, biophysics, and pharmacology expertise across 5 research institutes and 3 universities to identify compounds that selectively activate TLR4 signaling. These adjuvant candidates could improve vaccine efficacy for infectious diseases where current options fall short.

Contract Research

mid-size

Target: CROs specializing in immunology and inflammation assays

If you are a contract research organization offering drug screening services — this project built validated protocols for molecular modelling of TLR4-related compounds and established assay systems for measuring TLR4 activation. The consortium's 10 deliverables include standardized methods for studying interactions with MD-2 and CD14 components of the TLR4 system. Licensing these protocols could expand your service portfolio in the growing immunology drug discovery market.

Frequently asked

Quick answers

What would it cost to license these TLR4 modulators?

Based on available project data, no licensing terms or pricing are disclosed. The project was coordinated by a public university (Università degli Studi di Milano-Bicocca), so licensing would need to be negotiated directly with the institution's technology transfer office. As an MSCA training network, IP arrangements across the 10-partner consortium may involve multiple rights holders.

Can these compounds be produced at industrial scale?

Based on available project data, the compounds were developed and tested at laboratory and animal-model scale. No evidence of scale-up manufacturing or GMP production is provided. Moving from lab-synthesized modulators to industrial production would require significant process chemistry development and regulatory qualification.

What is the intellectual property situation?

The project involved 10 partners across 5 countries, including 2 industry partners and 1 SME. IP rights are likely shared under the MSCA-ITN consortium agreement. Any licensing arrangement would need to account for contributions from partners in Belgium, Germany, Spain, Italy, and Slovenia. Contact the coordinator for specific patent filings on the TLR4 modulators developed.

How close are these compounds to clinical use?

The project focused on developing compounds and assessing therapeutic potential on animal models. This places the technology at pre-clinical stage. Moving to clinical trials would require toxicology studies, GMP manufacturing, and regulatory submissions — typically requiring several more years and substantial investment.

Which diseases could these compounds treat?

According to the project objectives, the TLR4 modulators target autoimmune disorders, chronic inflammations, allergies, asthma, infectious diseases, CNS diseases, and cancer. The project specifically mentions three therapeutic applications: vaccine adjuvants, anti-sepsis agents, and anti-inflammatory agents for allergy and asthma treatment.

What validated tools came out of this project?

The project produced 10 deliverables, including documented protocols for molecular modelling of TLR4-related compounds. These protocols enable computational screening of candidate molecules that interact with the MD-2 and CD14 components of the TLR4 recognition system. These tools can be adopted by other research groups or companies working on TLR4-targeted drug discovery.

Consortium

Who built it

The TOLLerant consortium brings together 10 partners from 5 European countries, with a strong academic and research-institute base (3 universities and 5 research organizations) complemented by 2 industry partners including 1 SME. The 20% industry ratio is typical for a Marie Curie training network, where the emphasis is on training early-stage researchers rather than direct commercialization. The consortium is coordinated by Università degli Studi di Milano-Bicocca in Italy, a public university. For a business partner, the key takeaway is that while the scientific expertise is deep and multi-disciplinary — spanning chemistry, biology, biophysics, biochemistry, and pharmacology — commercial translation would require additional industry involvement and investment beyond what this training-focused network was designed to deliver.

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCACoordinator · IT
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNEparticipant · ES
UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO IIparticipant · IT
KEMIJSKI INSTITUTparticipant · SI
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIASparticipant · ES
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASparticipant · ES
VIB VZWparticipant · BE
UNIVERSITAET BIELEFELDparticipant · DE

How to reach the team

Università degli Studi di Milano-Bicocca, Italy — reach out via their technology transfer office or the project website

Order a report on this consortium See UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA profile →

Next steps

Talk to the team behind this work.

Want to explore licensing TLR4 modulator compounds or molecular modelling protocols from this consortium? SciTransfer can connect you with the right research team and navigate the multi-partner IP landscape.

Order a report on this topic More in Health & Biomedical